Search

RU-2026105456-A - A METHOD FOR TREATMENT OF BRAIN INJURY AFTER A STROKE

RU2026105456ARU 2026105456 ARU2026105456 ARU 2026105456ARU-2026105456-A

Inventors

  • ЛЮ, Чжи-жэнь

Assignees

  • ПРОДА БАЙОТЕК, ЭлЭлСи

Dates

Publication Date
20260507
Application Date
20240805
Priority Date
20230803

Claims (20)

  1. 1. A method for treating ischemia-reperfusion injury (IRI) of the brain in a subject, comprising administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant, wherein the PKM2 protein variant is delivered systemically and is capable of reducing tissue damage following reperfusion of ischemic brain tissue.
  2. 2. The method according to claim 1, wherein the variant of the PKM2 protein is the G415R mutant.
  3. 3. The method according to claim 1, wherein the brain damage is caused by a hemorrhagic stroke.
  4. 4. The method according to claim 1, wherein the brain damage is caused by ischemic stroke.
  5. 5. The method according to claim 1, wherein the PKM2 protein variant is administered systemically.
  6. 6. The method according to claim 1, wherein the PKM2 protein variant is administered at any time and within 2 hours after reperfusion.
  7. 7. A method for improving tissue recovery and reparation after ischemic stroke and reperfusion, as well as hemorrhagic stroke in a patient in need thereof, comprising administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant with the G415R mutation to damaged tissue, wherein the PKM2 protein variant is capable of preventing neuronal death and stimulating regeneration.
  8. 8. The method of claim 7, wherein the PKM2 protein variant is not a constitutive PKM2.
  9. 9. The method according to claim 7, wherein the ischemic stroke is an acute ischemic stroke.
  10. 10. A method for treating brain damage caused by hemorrhagic stroke in a subject, comprising administering a therapeutically effective amount of a PKM2 (pyruvate kinase M2) protein variant, wherein the PKM2 protein variant is delivered systemically and is capable of reducing damage to brain tissue.
  11. 11. A method for improving tissue recovery and reparation after ischemic stroke and reperfusion, as well as hemorrhagic stroke in a patient in need thereof, comprising administering a therapeutically effective amount of a mutant pyruvate kinase M2 (PKM2) with the G415R mutation to tissue damaged by ischemic stroke, wherein the composition prevents neuronal death and stimulates regeneration.
  12. 12. The method according to claim 11, wherein the variant RKM2 does not represent a constitutive RKM2.
  13. 13. The method according to claim 11, which preserves nerve tissue.
  14. 14. The method of claim 11, wherein the ischemic stroke is an acute ischemic stroke.
  15. 15. The method of claim 11, wherein the therapeutic agent comprises PKM2 obtained from a human or non-human animal.
  16. 16. The method of claim 11, wherein the therapeutic agent is placed in a pharmaceutically acceptable carrier.
  17. 17. The method according to claim 11, wherein the composition is administered systemically.
  18. 18. The method of claim 11, wherein the composition reduces the death of nerve cells induced by ischemic injury.
  19. 19. The method according to claim 11, wherein the composition improves the recovery of brain function after a stroke.
  20. 20. The method according to claim 11, wherein the pyruvate kinase M2 or variant is a dimer.